**Maternal folate nutrition and offspring health: evidence and current controversies**

Aoife Caffrey1, Helene McNulty1, Rachelle E. Irwin2, Colum P. Walsh2 and Kristina Pentieva1

**Author Affiliations**: 1Nutrition Innovation Centre for Food and Health (NICHE) and 2Genomic Medicine Group, School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, BT52 1SA

**Authors’ last names:** Caffrey, McNulty, Irwin, Walsh and Pentieva

**Corresponding Author**: Professor Helene McNulty, Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, BT52 1SA. Tel: +44 (0)28 7012 4583, E-mail: h.mcnulty@ulster.ac.uk.

**Shortened title (45 characters)**: Maternal folate status and offspring health

**Keywords**: Folate: Pregnancy: First 1000 days: Cognition: Epigenetics

**Abbreviations:** FA, folic acid; GW, gestational week; NTD, neural tube defect; RCT, randomised controlled trial.

**Word count**: 6740/7000 (excluding references)

**Abstract**

Periconceptional folic acid (FA) is known to have a protective effect in the prevention of neural tube defects (NTDs), leading to global recommendations for FA supplementation before and in early pregnancy. Maternal folate throughout pregnancy may have other roles in offspring health, including neurodevelopment and cognitive performance in childhood. Folate is essential for one-carbon metabolism, a network of pathways involved in several biological processes including nucleotide synthesis, DNA repair and methylation reactions. The evidence reviewed here shows a conclusive role for offspring health of maternal folate nutrition in early pregnancy and probable benefits in later pregnancy. Folate-mediated epigenetic changes in genes related to brain development and function offer a plausible biological basis to link maternal folate with effects in offspring brain, albeit this research is in its infancy. Mandatory FA fortification of food has proven to be highly effective in decreasing NTD cases in populations where it has been implemented, but this policy is controversial owing to concerns related to potential adverse effects of over-exposure to FA. In the absence of population-wide fortification, and given the generally poor compliance with current FA recommendations, optimising folate status of mothers in very early pregnancy for protection against NTD remains challenging. Thus, current policy in the UK, Ireland and elsewhere in Europe for the prevention of NTDs (based on periconceptional FA supplementation only), has proven to be largely ineffective. This review addresses the evidence and the controversies that surround this area, as well as identifying the challenges in translating policy into practice.

**Introduction**

Pregnancy represents a period of rapid tissue growth of maternal and fetal tissues that is associated with increased energy and nutrient requirements. Maternal nutrition during pregnancy, as part of the ‘first 1,000 days’, is widely recognised as being essential for optimal offspring development, reducing lifelong disease burden and for general health throughout life(1). In particular, folate plays a critical role in pregnancy as it is required for one-carbon metabolism, a network of metabolic pathways involved in nucleotide synthesis, DNA repair, methylation reactions and neurotransmitter synthesis and thus is essential during periods of rapid tissue growth(2). In early pregnancy, there is conclusive evidence that periconceptional folic acid (FA) supplementation has a beneficial effect in preventing neural tube defects (NTDs)(3,4). It is almost 30 years since two large clinical trials proved that periconceptional FA supplementation of mothers was essential in the prevention of NTDs. This led many countries worldwide to introduce mandatory FA food fortification programmes(5), whereas other countries (most notably within Europe) have chosen public health strategies promoting periconceptional FA supplementation only. Apart from NTDs, emerging evidence suggests that maternal folate throughout pregnancy may have other roles in offspring health, including neurodevelopment and cognitive performance in the first decade of life. This review will explore the evidence linking maternal folate status with offspring health and will consider the associated biological mechanisms. In addition, the challenge of translating the evidence to public health, and somewhat controversial policies, will be considered.

**Role of folate in human health**

*Metabolic role of folate*

Folate plays an essential role in one-carbon metabolism where it acts as a cofactor in DNA synthesis and repair, methylation and amino acid reactions (**Figure 1**). Within this network, folate coenzymes function in mediating the transfer and utilisation of one-carbon units in metabolic pathways involving interaction with vitamin B12, vitamin B6 and riboflavin(2). Reduced folates enter the one-carbon cycle as tetrahydrofolate (THF) which acquires a carbon unit from serine in a vitamin B6-dependent reaction and subsequently forms 5,10-methylene THF, which is required for the synthesis of nucleic acids, or converted to 5-methyl THF. Methylenetetrahydrofolate reductase (MTHFR) is the riboflavin (FAD)-dependent enzyme that catalyses the reduction of 5,10-methylene THF to 5-methyl THF. Within the methionine cycle, 5-methyl THF is required for the remethylation of homocysteine to methionine via the vitamin B12-dependent enzyme methionine synthase. Methionine in turn is required for the generation of S-adenosylmethionine (SAM), the essential methyl donor for innumerable genomic and nongenomic methylation reactions required for the nervous system(2). This pathway is essential for the methylation of DNA, by DNA methyltransferases using SAM as a cofactor, which can play a key role in controlling gene expression in a process referred to under the umbrella term epigenetics(6). Methylation is also essential in the synthetic pathways of neurotransmitters (dopamine, noradrenaline and serotonin), myelination and phospholipids and is thus important for normal brain function. Over the past 40 years, the association between neurology and B-vitamin status has been extensively investigated, with evidence that folate deficiency can lead to aberrant methylation and could in turn affect neurocognition(7).

*Role of folate in pregnancy*

The effect of folate status on pregnancy outcomes has long been recognised since the original discovery of folate by Lucy Wills in 1931, when marmite or other yeast extracts were found to be effective for the treatment of macrocytic anaemia in pregnant women(8); later it was discovered that the active factor was folate.

Pregnancy is recognised as a time when folate requirements are increased to sustain the demand for rapid cell division and growth of fetal, placental and maternal tissue. This reflects the critical role folate plays in DNA, RNA and protein synthesis(2). Along with the physiological changes related to the growth of maternal and fetal tissues, there is an expansion of plasma volume by 50% compared to an increase in the red blood cell (RBC) mass by 25%(9), increasing the demand for folate. Globally, the most common causes of anaemia of pregnancy (defined as a haemoglobin concentration of less than 11 g/dL, at any point during pregnancy(10)) are iron and/or folate deficiency, arising from increased fetal requirements and frequently aggravated by decreased maternal nutrient reserves(11). Numerous studies have illustrated that the prevalence of folate deficiency increases with advancing gestational age(12). A more recent trial in later pregnancy however showed that the decline in serum and RBC folate concentrations and increase in plasma homocysteine concentrations, that otherwise occur as pregnancy progresses, can be prevented by continued FA supplementation (0.4 mg/d) in trimesters 2 and 3 of pregnancy(13); which in turn may prevent anaemia in later pregnancy(14).

Observational studies have suggested that low maternal folate status is also associated with an increased risk of other adverse pregnancy outcomes including pre-eclampsia, gestational hypertension and pre-term delivery(15–17), while improved folate may help to prevent these conditions. In a study of 3,000 Canadian women, supplementation of multivitamins containing FA was associated with a reduced risk of pre-eclampsia(18), while in a study of 215 Korean pregnant women, FA supplementation was associated with significantly lower risk of pre-eclampsia(19). In contrast, one very recent international randomised trial found that high dose FA in pregnancy did not reduce pre-eclampsia in high-risk pregnancy(20). Notably, this study did not account for the common *MTHFR* C677Tpolymorphism which is associated with a significantly increased risk of hypertension and hypertension in pregnancy(21).

The demand for folate is also increased during lactation to support neonatal growth and development(16). Folates are actively transported across the mammary epithelium, thereby allowing breast-milk folate concentration to be maintained and preventing folate insufficiency in breast-fed infants, but this is at the expense of maternal folate status in the absence of supplementation(22). Only in the case of frank maternal folate deficiency is milk folate reported to decline to critically low concentrations(23).

**Maternal folate and offspring health**

*Neural tube defects and other congenital abnormalities*

Since the early 1990s, conclusive evidence has existed that periconceptional FA supplementation prevents the first occurrence(4) and recurrence of NTDs(3). This has led to worldwide recommendations that have been in place since 1992(24), for women of childbearing age to take 0.4 mg/d FA from before pregnancy until the end of the first trimester. NTDs, including spina bifida, anencephaly, encephalocele and hydrocephalus, are major birth defects that can lead to miscarriage, stillbirth, or to lifelong and usually severe disabilities. NTDs are the largest group of anomalies of the central nervous system characterised by incomplete closure of the embryonic neural tube and are among the most significant congenital causes of morbidity and mortality in infants worldwide(25,26). The conclusive evidence of the protective effect of FA comes from two RCTs, the first of which demonstrated that periconceptional supplementation at 4 mg/d FA in women with a history of NTD (*n* 1195), decreased the recurrence by 70%(3). The second trial by Czeizel and Dudas(4) in over 4,000 women, showed that periconceptional multiple micronutrient supplementation containing 0.8 mg/d FA prevented the first occurrence of NTDs.

These intervention studies, although not designed to test birth defects other than NTDs, yielded additional information on other congenital abnormalities. The aforementioned Czeizel and Dudas trial(4) was the subject of a subsequent analysis which found that the total rate of all major congenital abnormalities (including heart defects, oral facial clefts and urinary tract anomalies) were significantly reduced in women using FA-containing multivitamins during the periconceptional period(27). Consistent with these findings, FA fortification in Canada has been associated with an 11% reduction in the prevalence of overall congenital heart defects(28). A recent meta-analysis of 15 studies from countries worldwide reported a decreased risk of cleft lip, with or without cleft palate, when orofacial cleft prevalence was examined in pre- versus post- FA fortification periods(29).

*Offspring brain development*

Recent advances in behavioural neuroscience have shown the important roles that nutrition plays in brain development(30–33). Brain development begins at the very early stages of fetal life and continues after birth through early life. Initially, brain cells are formed followed by cell migration and differentiation, and the development of synapses to enable cells to communicate with one another(34). Myelin is the supportive tissue that surrounds and protects the nerve axons and facilitates communication. Nutrient deficiencies, such as inadequate folate intake, can interfere with early brain development and function, resulting in neuroanatomical, neurochemical, or neurometabolic changes that are expressed by restricting the myelination and synaptic connectivity(35) as well as changes in tissue levels of neurotransmitters (e.g., serotonin, dopamine, norepinephrine, and acetylcholine). The functional consequences of these alterations vary, depending on the specific nutritional deficiency and the timing of the deficiency relative to the development of the neurological structures(36). The last trimester of pregnancy until 2 years after birth, is a critical period of rapid growth and development of certain regions of the brain such as cortical and subcortical grey matter(32,37,38).

Myelination of the brain, which is most intensive from mid-gestation through the second year of life but continues through puberty, may be specifically vulnerable to B-vitamin deficiency(35). In infants, B-vitamin deficiencies have been associated with demyelination and brain atrophy(39). Thus continuation of FA supplementation after the first trimester (i.e. after the recommended period for the prevention of NTDs) may also be an important period for optimal folate status and prenatal brain development(34,36,40). Thus maternal folate nutritional status can influence both structural and functional development of the brain(41), while folate insufficiencies in pregnancy may result in lasting changes in brain function.

**Maternal folate and offspring cognitive performance**

The effect of maternal folate during pregnancy on cognitive performance of the offspring has been investigated in several studies, with evidence to date coming predominantly from observational research (**Table 1**)(42–57). Most of these studies have focused on reported FA supplement use or folate status of mothers in early pregnancy, whereas later pregnancy (i.e. beyond trimester 1) has rarely been investigated. A number of studies in early pregnancy have shown positive associations between self-reported FA supplement use and cognitive performance in the child(42,45,46). These findings are in general agreement with studies that found reduced cognitive ability in the offspring of mothers with suboptimal folate status(44,49). Likewise, one recent systematic review of 14 studies of maternal nutritional status in pregnancy and offspring cognitive function concluded that low maternal folate status was associated with poorer offspring cognitive function(58).

Compared with the aforementioned studies in early pregnancy, evidence provided by Gross *et al*(50) over 40 years ago showed that children born to mothers with diagnosed megaloblastic anaemia in the third trimester of pregnancy had abnormal neurodevelopment and lower intellectual abilities compared with infants born to mothers with optimal folate status. Several decades later, a longitudinal study of 256 mother-child pairs linked maternal folate deficiency in later pregnancy with reduced brain volume in the children aged 6-8 years, as measured using magnetic resonance imaging (MRI)(56). Further to this, a study investigating the impact of maternal blood folate, vitamin B12 and homocysteine concentrations at the 30th gestational week, showed that higher maternal folate status during later pregnancy predicted better cognitive performance in children age 9-10 years(52). There have however been two longitudinal observational studies that found no significant associations between blood folate status in later pregnancy and cognitive performance(51) or infant neurodevelopment(54).

A number of studies in this area have investigated offspring cognition in relation to reported use of FA above the recommended dose of 0.4 mg/d. One such study by Chatzi *et al*(53) found that self-reported FA supplement usage of 5 mg/d in later pregnancy was associated with enhanced vocabulary and verbal skills of the offspring in the first 2 years of life. In contrast, another European study found that FA supplement usage of >1 mg/d as reported by mothers was associated with reduced verbal and cognitive development, compared to the children of mothers with FA intakes of 0.4 mg/d during the 2nd and 3rd trimesters of pregnancy(55,57). In an effort to validate self-reported FA supplement use by mothers, Chatzi *et al*(53) collected cord blood samples and showed that mothers who reported high dose FA supplement usage gave birth to neonates with higher RBC folate concentrations in cord blood.

A major limitation in the aforementioned studies is that they are observational and thus, by design, cannot confirm whether a causal relationship between maternal folate nutrition and offspring cognitive performance exists. For example, some studies have found supplement usage to be more frequent among pregnant women at lowest nutritional risk(59), raising the possibility that FA usage may simply be a marker of positive health considerations and that another nutrient (or non-nutritional factor) could explain the observed relationship. Supplement usage is reported to be higher in pregnant women who are older, have higher household incomes, with higher educational attainment, have planned their pregnancy, have breastfed their child, live with a partner, do not smoke, and have a healthier weight(60–65); any one of these factors could actually explain the observed relationship between maternal FA supplement usage and offspring cognition.

A randomised trial could provide evidence of a causative link between maternal folate and offspring cognition, but most available RCTs have investigated the effect of multiple micronutrient supplements containing FA(66–71), as shown in **Table 2**. The only RCT to date to look at the specific effect of 0.4 mg/d FA in isolation was conducted at this centre, namely the Folic Acid Supplementation in the Second and Third Trimesters trial (FASSTT; ISRCTN19917787)(13) and provided a unique opportunity to specifically investigate the effect of FA supplementation in the 2nd and 3rd trimesters on subsequent cognitive performance of the child. The results showed that children of mothers supplemented with FA throughout pregnancy performed better in the cognitive domain at age 3 years(72) and the verbal domain at 7 years(73).

These findings are in agreement with the results of animal studies, whereby continuation of maternal FA supplementation increased serum folate concentrations in pregnant rat dams and improved neurodevelopment in their pups, from newborns to adulthood(74). Histological investigation from the same study found that continued FA supplementation throughout pregnancy stimulated hippocampal neurogenesis in the offspring by increasing proliferation and neuronal differentiation of neural stem cells, and also by enhancing synaptogenesis in cerebral cortex(75). Furthermore, offspring of pregnant rats fed an FA-deficient diet during gestation had a reduction of progenitor cells in the fetal neocortex(76) which is the part of the brain responsible for complex behaviours such as cognition, attention and social competence.

Overall, the evidence from human and animal studies appears to support a role of maternal folate status in influencing cognitive performance of the child. In addition to cognitive health, there are also human studies linking maternal folate throughout pregnancy with psychosocial behaviour(77) and cerebral cortex thickness in youths(78), which warrant further investigation. In summary, the totality of evidence in this area is promising, but remains inconclusive, given that the vast majority of human studies are observational and thus inherently limited.

**Epigenetic mechanisms linking maternal folate with offspring health**

Although the precise biological mechanism explaining the effect of FA during pregnancy on neurodevelopment of the child is unknown, it must involve the essential role of folate in one-carbon metabolism encompassing a complex network of interdependent pathways that support a variety of processes, including myelination, neurotransmitter synthesis and epigenetics, which in turn may impact neurodevelopment(35,79) (**Figure 1**). Epigenetic marks, in particular, and specifically DNA methylation, have been proposed as plausible mechanisms underlying associations between folate and various disease outcomes such as NTDs, cardiometabolic disorders and early life development(80).

Epigenetics refers to histone modification, RNA interference or DNA methylation which can exert heritable changes in gene expression that occur without altering the underlying DNA sequence(6). DNA methylation is the most widely studied and understood epigenetic mechanism for gene regulation and is dependent upon the supply of methyl donors provided by folate and the metabolically related B-vitamins via the production of SAM within one-carbon metabolism (**Figure 1**). SAM is an essential methyl donor for DNA and is therefore important for transcriptional regulation, thus folate deficiency could lead to aberrant gene expression and various consequential health outcomes(81). Early life development, ranging from preconception to childhood, is considered a critical window characterised by rapid DNA methylation changes, pronounced susceptibility to environmental factors and programming of epigenetic marks that may have long-lasting health effects(82).

There has been growing interest in the importance of maternal folate status, DNA methylation and offspring neurodevelopment(34,79). One cohort study of women who reported using FA supplements after the 12th GW of pregnancy (*n* 913) found that FA was associated with lower methylation in cord blood for both *LINE-1* and *PEG3*, and higher methylation for *IGF2*(83). The largest study to date (*n* 1988), investigated epigenome-wide DNA methylation in newborns from two European pregnancy cohorts, and reported an inverse association between maternal plasma folate during pregnancy and differential DNA methylation in cord blood across genes involved in folate biology and neurodevelopmental processes(84). Another study showed that maternal periconceptional FA use (as reported by mothers) was associated with increased methylation of *IGF2* in the offspring when measured at 17 months of age(85). However, a comprehensive review concluded that associations between maternal folate exposure and the offspring methylome were generally inconsistent, likely as a result of methodological differences between published studies, including differences in the form of folate used, timing of exposure, baseline folate status, underlying genotype and the genomic region affected(81).

The main limitation of studies in this area is that they are observational and therefore cannot provide evidence of a causal relationship between maternal folate during pregnancy and DNA methylation effects in offspring. The only randomised trial to date was carried out at this centre and showed significant folate-related changes in DNA methylation of the retrotransposon *LINE-1* and candidate genes related to brain development such as *IGF2* and *BDNF* in the newborn of mothers who received 0.4 mg/d FA compared to placebo in the 2nd and 3rd trimesters(86). These findings have also been supported by the results of animal experiments. One such animal study investigated DNA methylation in the brain and found that FA supplementation throughout pregnancy significantly increased brain folate concentrations in the newborn pups, while brain global DNA methylation incrementally decreased and was the lowest in pups whose mothers were supplemented with FA throughout their entire pregnancy(87). The findings offer a potential biological mechanism linking maternal folate status with neurodevelopment of the offspring, but this requires investigation using a genome-wide approach to more fully explore the underlying mechanisms.

In addition to maternal folate, vitamin B12 status has also been found to be a significant predictor of gene-specific DNA methylation in the offspring. Using a two-step ‘Mendelian randomisation study’ approach with data from the ALSPAC cohort, an effect of maternal serum vitamin B12 concentrations on cord blood DNA methylation, and an effect of vitamin B12-responsive DNA methylation changes on children’s cognition at 8 years, were identified(88). The finding that vitamin B12 may also influence DNA methylation in a similar way to folate is not surprising as it acts synergistically with folate within one-carbon metabolic cycle and both vitamins are required for the generation of SAM(2) (**Figure 1**).

Although the link between maternal nutrition and offspring health has been extensively studied, understanding of how the paternal diet could influence offspring health remains relatively under-investigated. One recent review however concluded that suboptimal paternal nutrition around the time of conception can play an important role in offspring health(89). In particular, the role of paternal nutrition in relation to sperm quality is emerging as potentially mediating offspring health(90,91). Mechanistically, both direct (sperm quality, epigenetic status, DNA integrity) and indirect (seminal fluid composition) paternal characteristics have been identified; in mice these mechanisms have been shown to affect offspring development across multiple generations(92). In terms of the epigenetic effects, both DNA methylation(93) and small RNA species(92) have been implicated as agents for the transmission of effects via the sperm.

So far, compelling evidence has suggested a role for epigenetics and DNA methylation in explaining the effects of nutrition in pregnancy on long-term offspring health outcomes. Folate-mediated epigenetic changes in genes related to brain development and function offer a biological basis to link maternal folate with offspring cognitive effects. Although this area of research is still in its infancy, future studies from RCT cohorts using an epigenome-wide approach will be necessary to more fully explore the underlying mechanisms.

**Optimising folate status in women of reproductive age**

*Food folates, folic acid and bioavailability*

There are three options to achieve optimal folate status in individuals and in populations, namely through naturally-occurring food folates, fortified foods and supplements. Food folates exist predominantly in the polyglutamyl form and are converted to monoglutamates for absorption, whereas FA, the synthetic vitamin form found in fortified foods and supplements, is a monoglutamate. In addition, natural folates are reduced molecules, whereas FA is fully oxidised(2). As a result, naturally occurring food folates show incomplete bioavailability compared with FA at equivalent levels of intake(94). Apart from their limited bioavailability once in the body, food folates are inherently unstable during cooking, and this can substantially reduce the folate content of these food before they are even ingested(95). In contrast, FA provides a highly stable and bioavailable form of the vitamin. The bioavailability of FA is assumed to be 100% when ingested as a supplement, while FA in fortified food is estimated to have about 85% the bioavailability of FA supplements(96). Folate intakes and recommendations in the USA and other countries are therefore now expressed as Dietary Folate Equivalents (DFEs), a calculation that considers the greater bioavailability of FA compared to naturally occurring food folates(97).

Owing to the instability and poor bioavailability of natural food folates, the potential to optimise folate status through food folates alone is relatively ineffective, whereas intervention with FA supplements or FA fortified food has been shown to be highly effective in optimising folate biomarker status in women of reproductive age(98).

*Folic acid recommendations for NTD prevention*

Once conclusive evidence had become available to show that FA supplementation could prevent the first occurrence(4) and recurrence of NTDs(3), committees worldwide produced recommendations for women of childbearing age to take 0.4 mg/d FA from before pregnancy until the end of the first trimester(24,99). These recommendations, which have been in place for almost 30 years, are challenging for a number of reasons. An estimated 50% of pregnancies are unplanned(100) and for many women the very early stage of pregnancy (when the neural tube is closing) may have passed before supplementation is even started. Therefore, in many cases the malformations of NTD may have occurred before a woman even knows that she is pregnant.

There is evidence from nearly 500,000 pregnant women that only 31% took FA supplements before pregnancy, with women under 20 years of age and non-caucasian women being the least likely to take FA as recommended(101). Therefore, the public health measure of recommending FA supplements before pregnancy has substantial limitations and is putting young women and those in ethnic minorities at a particular disadvantage(101). Research from Northern Ireland(102) and the Republic of Ireland(103) indicates low levels of compliance among Irish women surveyed during pregnancy, between 14% and 44% reporting to have taken FA supplements as recommended in the periconceptional period. This is of concern given that the benefit of FA supplementation in preventing NTDs is confined to those women (the minority) who follow the recommendations correctly.

The measurement of RBC folate in women of reproductive age is a useful way to assess NTD risk within populations on the basis of the known continuous dose-response inverse relationship between maternal RBC folate concentrations and NTD(104). On this basis, the WHO has established guidelines for optimal RBC folate concentrations of 906 nmol/L in women of reproductive age for the prevention of NTDs(105). In the UK, where there is voluntary (but not mandatory) fortification of foods with FA, the percentage of women with insufficient RBC folate concentrations (<906 nmol/L) to prevent folate-responsive NTDs is estimated to be 83% in Northern Ireland, 81% in Scotland and 79% in Wales(106). Also, evidence from the National Adult Nutrition Survey (NANS) in Ireland showed that non-consumers of FA from fortified food or supplements were at particularly high risk of suboptimal folate status, again using the cut-point of 906 nmol/L RBC folate to define optimal status(107).

*Folic acid fortification and NTD prevalence*

The indisputable protective role of FA in the prevention of NTDs, coupled with the low compliance of women to FA recommendations, has stimulated the option of mandatory FA fortification, a policy now in place in over 80 countries worldwide(5). Mandatory food fortification requires food manufacturers to add FA to certain foods (e.g. flour or grain products), whereas voluntary fortification allows FA to be added to foods at the discretion of manufacturers. A systematic review and meta-analysis of global birth prevalence of spina bifida by FA fortification status found that spina bifida prevalence was significantly lower in studies from countries where FA fortification was mandatory (3.4 per 10,000 live births) compared to countries with where fortification was voluntary or non-existent (4.8 per 10,000 live births)(108). Furthermore, evidence has shown that in 2017 only 18% of FA-preventable NTD cases globally were prevented, resulting in 230,000 children with either spina bifida or anencephaly(109). In the US, after the implementation of mandatory FA fortification, reported rates of NTD prevalence decreased by 35%, from 10.7 to 7.0 NTDs per 10,000 live births, preventing over 1,300 NTDs annually(110–112). In Canada, the prevalence of NTDs decreased by 46%, from 15.8 per 10,000 births before FA food fortification to 8.6 per 10,000 births after implementation of mandatory fortification(113).

In contrast, public health strategies based on promoting increased awareness of the benefits of FA supplementation, as in place in European countries, have been shown to be largely ineffective(114–116). Analysis of European data showed that average infant mortality with congenital anomaly was 1.1 per 1000 births, with higher rates where termination of pregnancy is illegal (Malta 3.0 and Ireland 2.1)(117). These rates have shown no downward trend over time, even with the introduction of government recommendations for FA usage, and NTD rates in 2011 were found to be comparable to that in 1991 (~0.9 per 1000 births)(114,115). As a result, one report investigating the period 2000-2010 estimated 1.6-fold higher NTD prevalence in European countries compared to countries with mandatory food fortification in place(116).

Ireland is recognised as having one of the highest rates of NTD-affected pregnancies in the world and there are concerns that the incidence of NTDs is increasing in recent years(115). In 2016, following an extensive review, the Food Safety Authority of Ireland (FSAI) scientific committee published an updated report recommending that mandatory fortification of bread or flour with FA should be implemented(103). Similarly, The UK Scientific Advisory Committee on Nutrition (SACN) has recently confirmed its longstanding advice that mandatory fortification of cereal flours with FA should be introduced for the prevention of NTDs(118). Legislation to implement mandatory FA fortification has yet to be introduced in either country.

**Current controversies and public health challenges**

FA, the synthetic form of folate, is used for food fortification and supplementation purposes. Once ingested, FA is reduced by dihydrofolate reductase (DHFR), and after subsequent methylation, it is released in the systemic circulation as 5-methyl THF. However, the reduction of FA is a slow process that is influenced by individual variations in DHFR activity(2), and thus exposure to high oral doses of FA can result in the appearance of unmetabolised FA in the circulation(119). The latter is not a normal constituent of plasma or other tissues. On this basis, concerns have been raised regarding potential (although as yet unconfirmed) adverse health effects of unmetabolised FA arising in the circulation through high FA exposures from supplements and fortified foods.

One issue was the historical concern that long-term exposure to high dose FA intakes might mask the macrocytic anaemia of vitamin B12 deficiency, common in older people, while allowing the associated irreversible neurologic symptoms to progress(120). Furthermore, analyses of NHANES (1999–2002) data in the United States showed that in elderly participants with low vitamin B-12 status, the presence of unmetabolised FA in serum was associated with worse cognitive performance compared to those with low vitamin B-12 status and no detectable FA in the circulation(121). Subsequent studies have not been able to confirm such effects(122,123), therefore these particular findings remain rather controversial. Other evidence has suggested that FA doses in excess of 1 mg/d may promote the growth of new or already existing but undiagnosed colorectal adenomas in those with pre-existing lesions(124). One recent meta-analysis (involving 50,000 individuals) however concluded that FA supplementation neither increased nor decreased site-specific cancer within the first 5 years of treatment(125), whilst one review reported decreases in cancer rates since the introduction of mandatory FA fortification in the USA(126).

A number of observational studies conducted in countries with either mandatory or voluntary FA food fortification have found detectable amounts of unmetabolised FA in the circulation of pregnant women(127–130) and newborns(127,129–132). Although it remains to be proven whether there are adverse effects associated with unmetabolised FA in the circulation, pregnancy may be of particular interest in this context as a vulnerable time of the life cycle. Moreover, the usage of FA supplements during pregnancy is widespread because FA is recommended worldwide from preconception until the end of the first trimester for protection against NTDs, and in later pregnancy, it is often prescribed by obstetricians for the treatment and prevention of folate deficiency anaemia. The only randomised trial in this area, previously carried out by this research group, provides evidence that continuing FA supplementation at a dose of 0.4 mg/d throughout the second and third trimesters (over and above FA intakes through fortified foods), results in no detectable unmetabolised FA concentrations in cord blood, despite improving folate status of mothers and neonates(133). Thus, in the event that adverse effects of unmetabolised FA are ever proven, this evidence indicates that the exposure of pregnant women to 0.4mg FA/d will have little impact.

Even though the risk-benefit debate surrounding food fortification with FA continues among policymakers, the totality of the evidence at this time suggests that adverse effects associated with FA overexposure are unlikely at the generally low FA levels arising through mandatory food fortification.

**Conclusions**

Maternal FA supplementation before and in early pregnancy is known to have beneficial effects in the prevention of NTDs. Emerging evidence suggests that it may also be beneficial for fetal brain development in later pregnancy. Mechanistically, the known role of folate in one-carbon metabolism and thus in methylation of proteins and DNA, provides a biological basis to link maternal folate with offspring health mediated via epigenetic effects. However, this area of research is still in its infancy and the role of maternal folate status during pregnancy on the offspring, and subsequent long-term health effects, requires further investigation in carefully designed studies.

Although there are clear recommendations in place worldwide for the prevention of NTDs through FA supplementation before and during early pregnancy, for many women the very early stage when the neural tube is closing may have passed before supplementation is even started. Thus, current health strategies in the UK, Ireland and the rest of Europe for the prevention of NTDs (based on periconceptional FA supplementation only), have been shown to be largely ineffective. Mandatory food fortification with FA offers a solution that has proved to be highly effective in decreasing NTD cases in populations where it has been implemented, but this policy is controversial owing to concerns related to potential adverse effects of over-exposure to FA. In the absence of population-wide fortification, and given the generally poor compliance of women with current FA recommendations, optimising folate status of mothers at the very early stage of pregnancy for protection against NTD remains challenging.

**Acknowledgements**

None.

**Financial Support**

This work was supported by the HSC Research and Development Division of the Public Health Agency, Northern Ireland (Enabling Research Award STL/5043/14), joint funding (Grant Ref: ES/N000323/1 “EpiFASSTT”) from the Biology and Biological Sciences Research Council (BBSRC) and the Economic and Social Research Council (ESRC) and from the Northern Ireland Department for Economy (DfE), which funded the PhD studentship for A.C. The funders had no role in the design, analysis or writing of this article.

**Conflicts of Interest**

None.

**Authorship**

A.C. drafted the manuscript; K.P., H.McN., C.P.W. and R.E.I. critically revised the manuscript for important intellectual content. All the authors have read and approved the final manuscript.

**References**

1. McDonald C & Thorne-Lyman A (2017) The Importance of the First 1,000 Days: An Epidemiological Perspective. In *The Biology of the First 1,000 Days*, pp 3-16 [CD Karakochuk, KC Whitfield, TJ Green, K Kraemer, editors]. Florida: CRC Press.

2. Bailey LB, Stover PJ, McNulty H *et al*. (2015) Biomarkers of nutrition for development— folate review. *J Nutr* **147**, 1636S–1680S.

3. MRC Vitamin Study Research Group (1991) Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* **338**, 131–137.

4. Czeizel AE & Dudas I (1992) Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* **327**, 1832–1835.

5. Food Fortification Initiative (2018) Global Progress of Industrially Milled Cereal Grains. http://www.ffinetwork.org/global\_progress/index.ph. (accessed October 2018).

6. Armstrong L (2014) *Epigenetics*. New York: Garland Science.

7. Reynolds EH (2014) The neurology of folic acid deficiency. *Handb Clin Neurol* **120**, 927–943.

8. Wills L (1931) Treatment of “pernicious anaemia of pregnancy” and “tropical anaemia” with special reference to yeast extract as a curative agent. *Br Med J* **1**, 1059–1064.

9. Milman N, Byg K & Agger A (2000) Hemoglobin and erythrocyte indices during normal pregnancy and postpartum in 206 women with and without iron supplementation. *Obs Gynecol Scand* **79**, 89–98.

10. WHO (2001) *Iron deficiency anaemia: assessment, prevention and control.* Geneva: World Health Organization.

11. Lee A & Okam M (2011) Anemia in pregnancy. *Hematol Oncol Clin North Am* **25**, 241–259.

12. Ackurt F, Wetherilt H, Loker M *et al*. (1995) Biochemical assessment of nutritional status in pre- and post-natal Turkish women and outcome of pregnancy. *Eur J Clin Nutr* **49**, 613–622.

13. McNulty B, McNulty H, Marshall B *et al*. (2013) Impact of continuing folic acid after the first trimester of pregnancy: findings of a randomized trial of folic acid supplementation in the second and third trimesters. *Am J Clin Nutr* **98**, 92–98.

14. Lassi ZS, Salam RA, Haider BA *et al*. (2013) Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes. *Cochrane Database Syst Rev* **3**, CD006896.

15. Lindblad B, Zaman S, Malik A *et al*. (2005) Folate, vitamin B12, and homocysteine levels in South Asian women with growth-retarded fetuses. *Acta Obstet Gynecol Scand* **84**, 1055–1061.

16. Tamura T & Picciano MF (2006) Folate and human reproduction. *Am J Clin Nutr* **83**, 993–1016.

17. Czeizel AE, Puhó EH, Langmar Z *et al*. (2010) Possible association of folic acid supplementation during pregnancy with reduction of preterm birth: a population-based study. *Eur J Obstet Gynecol Reprod Biol* **148**, 135–140.

18. Wen SW, Chen XK, Rodger M *et al*. (2008) Folic acid supplementation in early second trimester and the risk of preeclampsia. *Am J Obstet Gynecol* **198**, 45–47.

19. Kim MW, Ahn KH, Ryu KJ *et al*. (2014) Preventive effects of folic acid supplementation on adverse maternal and fetal outcomes. *PLoS One* **9**, e97273.

20. Wen SW, White RR, Rybak N *et al*. (2018) Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. *BMJ* **362**, k3478.

21. McNulty H, Strain JJ, Hughes CF *et al*. (2017) Riboflavin, MTHFR genotype and blood pressure: a personalized approach to prevention and treatment of hypertension. *Mol Aspects Med* **53**, 2–9.

22. Mackey AD & Picciano MF (1999) Maternal folate status during extended lactation and the effect of supplemental folic acid. *Am J Clin Nutr* **69**, 285–292.

23. Metz J, Zalusky R & Herbert V (1968) Folic acid binding by serum and milk. *Am J Clin Nutr* **21**, 289–297.

24. CDC (1992) Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. *MMWR Recomm Rep* **41**, 1–7.

25. Zaganjor I, Sekkarie A, Tsang BL *et al*. (2016) Describing the prevalence of neural tube defects worldwide: a systematic literature review. *PLoS One* **11**, e0151586.

26. Botto L, Moore CA, Khoury M *et al*. (1999) Neural tube defects. *N Engl J Med* **341**, 1509–1519.

27. Czeizel AE (1993) Prevention of congenital abnormalities by periconceptional multivitamin supplementation. *BMJ* **306**, 1645–1648.

28. Liu S, Joseph KS, Luo W *et al*. (2016) Effect of folic acid food fortification in Canada on congenital heart disease subtypes. *Circulation* **134**, 647–655.

29. Millacura N, Pardo R, Cifuentes L *et al*. (2017) Effects of folic acid fortification on orofacial clefts prevalence: a meta-analysis. *Public Health Nutr* **20**, 2260–2268.

30. Fernstrom JD (2000) Can nutrient supplements modify brain function ? *Am J Clin Nutr* **71**, Suppl. 6, S1669-S1673.

31. Georgieff MK (2007) Nutrition and the developing brain: nutrient priorities and measurement. *Am J Clin Nutr* **85**, S614–S620.

32. Isaacs EB (2013) Neuroimaging, a new tool for investigating the effects of early diet on cognitive and brain development. *Front Hum Neurosci* **7**, Article 445, 1-12.

33. Nyaradi A, Li J, Hickling S *et al*. (2013) The role of nutrition in children’s neurocognitive development, from pregnancy through childhood. *Front Hum Neurosci* **7**, 97.

34. Irwin RE, Pentieva K, Cassidy T *et al*. (2016) The interplay between DNA methylation, folate and neurocognitive development. *Epigenomics* **8**, 863–879.

35. Black MM (2008) Effects of vitamin B12 and folate deficiency on brain development in children. *Food Nutr Bull* **29**, Suppl. 2, S126-S131.

36. Roffman JL (2018) Neuroprotective effects of prenatal folic acid supplementation: why timing matters. *JAMA Psychiatry* **75**, 747–748.

37. Hasegawa M, Houdou S, Mito T *et al*. (1992) Development of myelination in the human fetal and infant cerebrum: a myelin basic protein immunohistochemical study. *Brain Dev* **14**, 1–6.

38. Gilmore JH, Shi F, Woolson SL *et al*. (2012) Longitudinal development of cortical and subcortical gray matter from birth to 2 years. *Cereb Cortex* **22**, 2478–2485.

39. Lövblad KO, Ramelli G, Remonda L *et al*. (1997) Retardation of myelination due to dietary vitamin B12 deficiency: cranial MRI findings. *Pediatr Radiol* **27**, 155–158.

40. McGarel C, Pentieva K, Strain JJ *et al*. (2015) Emerging roles for folate and related B-vitamins in brain health across the lifecycle. *Proc Nutr Soc* **74**, 46–55.

41. Georgieff MK, Brunette KE & Tran P V. (2015) Early life nutrition and neural plasticity. *Dev Psychopathol* **27**, 411–423.

42. Julvez J, Fortuny J, Mendez M *et al*. (2009) Maternal use of folic acid supplements during pregnancy and four-year-old neurodevelopment in a population-based birth cohort. *Paediatr Perinat Epidemiol* **23**, 199–206.

43. del Río Garcia C, Torres-Sánchez L, Chen J *et al*. (2009) Maternal MTHFR 677C>T genotype and dietary intake of folate and vitamin B 12: their impact on child neurodevelopment. *Nutr Neurosci* **12**, 13–20.

44. Schlotz W, Jones A, Phillips DIW *et al*. (2010) Lower maternal folate status in early pregnancy is associated with childhood hyperactivity and peer problems in offspring. *J Child Psychol Psychiatry Allied Discip* **51**, 594–602.

45. Roth C, Magnus P, Schjølberg S *et al*. (2011) Folic acid supplements in pregnancy and severe language delay in children. *JAMA* **306**, 1566–1573.

46. Villamor E, Rifas-Shiman SL, Gillman MW *et al*. (2012) Maternal intake of methyl-donor nutrients and child cognition at 3 years of age. *Paediatr Perinat Epidemiol* **26**, 328–335.

47. Boeke CE, Gillman MW, Hughes MD *et al*. (2013) Choline intake during pregnancy and child cognition at age 7 years. *Am J Epidemiol* **177**, 1338–1347.

48. Polańska K, Muszyński P, Sobala W *et al*. (2015) Maternal lifestyle during pregnancy and child psychomotor development - Polish Mother and Child Cohort study. *Early Hum Dev* **91**, 317–325.

49. Murphy MM, Fernandez-Ballart JD, Molloy AM *et al*. (2016) Moderately elevated maternal homocysteine at preconception is inversely associated with cognitive performance in children 4 months and 6 years after birth. *Matern Child Nutr* **13**, e12289.

50. Gross R, Newberne P & Reid J (1974) Adverse effects on infant development associated with maternal folic acid deficiency. *Nutr Rep Int* **10**, 241–248.

51. Tamura T, Goldenberg RL, Chapman VR *et al*. (2005) Folate status of mothers during pregnancy and mental and psychomotor development of their children at five years of age. *Pediatrics* **116**, 703–708.

52. Veena SR, Krishnaveni G V, Srinivasan K *et al*. (2010) Higher maternal plasma folate but not vitamin B-12 concentrations during pregnancy are associated with better cognitive function scores in 9- to 10- year-old children in South India. *J Nutr* **140**, 1014–1022.

53. Chatzi L, Papadopoulou E, Koutra K *et al*. (2012) Effect of high doses of folic acid supplementation in early pregnancy on child neurodevelopment at 18 months of age: the mother-child cohort “Rhea” study in Crete, Greece. *Public Health Nutr* **15**, 1728–1736.

54. Wu BTF, Dyer RA, King DJ *et al*. (2012) Early second trimester maternal plasma choline and betaine are related to measures of early cognitive development in term infants. *PLoS One* **7**, e43448.

55. Valera-Gran D, García De La Hera M, Navarrete-Muñoz EM *et al*. (2014) Folic acid supplements during pregnancy and child psychomotor development after the first year of life. *JAMA Pediatr* **168**, e142611.

56. Ars CL, Nijs IM, Marroun HE *et al*. (2016) Prenatal folate, homocysteine and vitamin B12 levels and child brain volumes, cognitive development and psychological functioning: the Generation R Study. *Br J Nutr*, 1–9. doi: 10.1017/S0007114515002081.

57. Valera-Gran D, Navarrete-Muñoz EM, De La Hera MG *et al*. (2017) Effect of maternal high dosages of folic acid supplements on neurocognitive development in children at 4-5 y of age: the prospective birth cohort Infancia y Medio Ambiente (INMA) study. *Am J Clin Nutr* **106**, 878–887.

58. Veena SR, Gale CR, Krishnaveni G V. *et al*. (2016) Association between maternal nutritional status in pregnancy and offspring cognitive function during childhood and adolescence; a systematic review. *BMC Pregnancy Childbirth* **16**, 220.

59. Malek L, Umberger WJ, Makrides M *et al*. (2018) Understanding motivations for dietary supplementation during pregnancy: a focus group study. *Midwifery* **57**, 59–68.

60. Watson LF, Brown SJ & Davey M-A (2006) Use of periconceptional folic acid supplements in Victoria and New South Wales, Australia. *Aust N Z J Public Health* **30**, 42–49.

61. Knudsen VK, Hansen HS, Ovesen L *et al*. (2007) Iron supplement use among Danish pregnant women. *Public Health Nutr* **10**, 1104–1110.

62. Timmermans S, Jaddoe VWV, Mackenbach JP *et al*. (2008) Determinants of folic acid use in early pregnancy in a multi-ethnic urban population in The Netherlands: The Generation R study. *Prev Med (Baltim)* **47**, 427–432.

63. Pouchieu C, Lévy R, Faure C *et al*. (2013) Socioeconomic, lifestyle and dietary factors associated with dietary supplement use during pregnancy. *PLoS One* **8**, e70733.

64. Nelson CRM, Leon JA & Evans J (2014) The relationship between awareness and supplementation: which Canadian women know about folic acid and how does that translate into use? *Can J Public Heal* **105**, 40–46.

65. Malek L, Umberger W, Makrides M *et al*. (2016) Poor adherence to folic acid and iodine supplement recommendations in preconception and pregnancy: a cross-sectional analysis. *Aust NZ J Public Health* **40**, 424–429.

66. Dobó M & Czeizel AE (1998) Long-term somatic and mental development of children after periconceptional multivitamin supplementation. *Eur J Pediatr* **157**, 719–723.

67. Christian P, Murray-Kolb LE, Khatry SK *et al*. (2010) Prenatal micronutrient supplementation and intellectual and motor function in early school-aged children in Nepal. *JAMA* **304**, 2716–2723.

68. Campoy C, Escolano-Margarit M V, Ramos R *et al*. (2011) Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age. *Am J Clin Nutr* **94**, Suppl., S1880-S1888.

69. Prado E., Alcock K, Muadz H *et al*. (2012) Maternal multiple micronutrient supplements and child cognition: a randomized trial in Indonesia. *Pediatrics* **130**, e536–e546.

70. Catena A, Munoz-Machicao JA, Torres-Espinola FJ *et al*. (2016) Folate and long-chain polyunsaturated fatty acid supplementation during pregnancy has long-term effects on the attention system of 8.5-y-old offspring: a randomized controlled trial. *Am J Clin Nutr* **103**, 115–127.

71. Prado EL, Sebayang SK, Apriatni M *et al*. (2017) Maternal multiple micronutrient supplementation and other biomedical and socioenvironmental influences on children’s cognition at age 9–12 years in Indonesia: follow-up of the SUMMIT randomised trial. *Lancet Glob Heal* **5**, e217–e228.

72. Pentieva K, McGarel C, McNulty BA *et al*. (2012) Effect of folic acid supplementation during pregnancy on growth and cognitive development of the offspring: a pilot follow-up investigation of children of FASSTT study participants. *Proc Nutr Soc* **71 (OCE2)**, E139 (Abstr).

73. McGarel C, McNulty H, Strain J *et al*. (2014) Effect of folic acid supplementation during pregnancy on cognitive development of the child at 6 years: preliminary results from the FASSTT Offspring Trial. *Proc Nutr Soc* **73 (OCE2)**, E49 (Abstr).

74. Wang X, Li W, Li S *et al*. (2018) Maternal folic acid supplementation during pregnancy improves neurobehavioral development in rat offspring. *Mol Neurobiol* **55**, 2676–2684.

75. Wang X, Li W, Li Z *et al*. (2018) Maternal folic acid supplementation during pregnancy promotes neurogenesis and synaptogenesis in neonatal rat offspring. *Cereb Cortex*, doi: 10.1093/cercor/bhy207.

76. Craciunescu CN, Brown EC, Mar M-H *et al*. (2004) Folic acid deficiency during late gestation decreases progenitor cell proliferation and increases apoptosis in fetal mouse brain. *J Nutr* **134**, 162–166.

77. Henry LA, Cassidy T, Mclaughlin M *et al*. (2018) Folic Acid Supplementation throughout pregnancy: psychological developmental benefits for children. *Acta Paediatr* **107**, 1370–1378.

78. Eryilmaz H, Dowling KF, Huntington FC *et al*. (2018) Association of prenatal exposure to population-wide folic acid fortification with altered cerebral cortex maturation in youths. *JAMA Psychiatry* **75**, 918–928.

79. Gabbianelli R & Damiani E (2018) Epigenetics and neurodegeneration: role of early-life nutrition. *J Nutr Biochem* **57**, 1–13.

80. Kok DE, Steegenga WT & Mckay JA (2018) Folate and epigenetics: why we should not forget bacterial biosynthesis. *Epigenomics* **10**, 1147–1150.

81. James P, Sajjadi S, Tomar AS *et al*. (2018) Candidate genes linking maternal nutrient exposure to offspring health via DNA methylation: a review of existing evidence in humans with specific focus on one-carbon metabolism. *Int J Epidemiol*, doi: 10.1093/ije/dyy153.

82. Numata S, Ye T, Hyde TM *et al*. (2012) DNA methylation signatures in development and aging of the human prefrontal cortex. *Am J Hum Genet* **90**, 260–272.

83. Haggarty P, Hoad G, Campbell DM *et al*. (2013) Folate in pregnancy and imprinted gene and repeat element methylation in the offspring. *Am J Clin Nutr* **97**, 94–99.

84. Joubert BR, den Dekker HT, Felix JF *et al*. (2016) Maternal plasma folate impacts differential DNA methylation in an epigenome-wide meta-analysis of newborns. *Nat Commun* **7**, 10577.

85. Steegers-Theunissen RP, Obermann-Borst SA, Kremer D *et al*. (2009) Periconceptional maternal folic acid use of 400 microg per day is related to increased methylation of the IGF2 gene in the very young child. *PLoS One* **4**, e7845.

86. Caffrey A, Irwin RE, McNulty H *et al*. (2018) Gene-specific DNA methylation in newborns in response to folic acid supplementation during the second and third trimesters of pregnancy: epigenetic analysis from a randomized controlled trial. *Am J Clin Nutr* **107**, 566–575.

87. Ly A, Ishiguro L, Kim D *et al*. (2016) Maternal folic acid supplementation modulates DNA methylation and gene expression in the rat offspring in a gestation period-dependent and organ-specific manner. *J Nutr Biochem* **33**, 103–110.

88. Caramaschi D, Sharp GC, Nohr EA *et al*. (2017) Exploring a causal role of DNA methylation in the relationship between maternal vitamin B12 during pregnancy and child’s IQ at age 8, cognitive performance and educational attainment: a two-step Mendelian randomization study. *Hum Mol Genet* **26**, 3001–3013.

89. Fleming TP, Watkins AJ, Velazquez MA *et al*. (2018) The Lancet Preconception Health Series: Origins of lifetime health around the time of conception: causes and consequences. *Lancet* **391**, 1842–1852.

90. Palmer NO, Bakos HW, Owens JA *et al*. (2012) Diet and exercise in an obese mouse fed a high fat diet improves metabolic health and reverses perturbed sperm function. *Am J Physiol Endocrinol Metab* **302**, 768–780.

91. Sinclair KD & Watkins AJ (2014) Parental diet, pregnancy outcomes and offspring health: metabolic determinants in developing oocytes and embryos. *Reprod Fertil Dev* **26**, 99–114.

92. Cropley JE, Eaton SA, Aiken A *et al*. (2016) Male-lineage transmission of an acquired metabolic phenotype induced by grand-paternal obesity. *Mol Metab* **5**, 699–708.

93. Radford EJ, Ito M, Shi H *et al*. (2014) In utero undernourishment perturbs the adult sperm methylome and intergenerational metabolism. *Science* **345**, 1255903.

94. McNulty H & Pentieva K (2004) Folate bioavailability. *Proc Nutr Soc* **63**, 529–536.

95. McKillop DJ, Pentieva K, Daly D *et al*. (2002) The effect of different cooking methods on folate retention in various foods that are amongst the major contributors to folate intake in the UK diet. *Br J Nutr* **88**, 681.

96. Pfeiffer CM, Rogers LM, Bailey LB *et al*. (1997) Absorption of folate from fortified cereal-grain products and of supplemental folate consumed with or without food determined by using a dual-label stable-isotope protocol. *Am J Clin Nutr* **66**, 1388–1397.

97. IOM (1998) Folate. In *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline* . Washington: National Academy Press, pp 196–305.

98. Cuskelly GJ, McNulty H & Scott JM (1996) Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. *Lancet* **347**, 657–659.

99. Department of Health (1992) *Folic acid and the prevention of neural tube defects. Report of an Expert Advisory Group for the Department of Health*. London.

100. Mills JL & Dimopoulos A (2015) Folic acid fortification for Europe? *Br Med J* **351**, h6198.

101. Bestwick JP, Huttly WJ, Morris JK *et al*. (2014) Prevention of neural tube defects: a cross-sectional study of the uptake of folic acid supplementation in nearly half a million women. *PLoS One* **9**, e89354.

102. McNulty B, Pentieva K, Marshall B *et al*. (2011) Womens compliance with current folic acid recommendations and achievement of optimal vitamin status for preventing neural tube defects. *Hum Reprod* **26**, 1530–1536.

103. FSAI (2016) *Update Report on Folic Acid and the Prevention of Birth Defects in Ireland*. Dublin: Food Safety Authority of Ireland.

104. Daly L, Kirke PM, Molloy A *et al*. (1995) Folate levels and nerual tube defects. *JAMA* **274**, 1698–1702.

105. WHO (2015) *Guideline: optimal serum and red cell folate concentrations in women of reproductive age for prevention of neural defects*. Geneva: World Health Organization.

106. Public Health England (2017) *National Diet and Nutrition Survey Rolling Programme (NDNS) Supplementary Report: Blood folate results for the UK as a whole, Scotland, Northern Ireland (Years 1 to 4 combined) and Wales (Years 2 to 5 combined). Revised 2017.* London: Public Health England.

107. Hopkins SM, Gibney MJ, Nugent AP *et al*. (2015) Impact of voluntary fortification and supplement use on dietary intakes and biomarker status of folate and vitamin B-12 in Irish adults. *Am J Clin Nutr* **101**, 1163–1172.

108. Atta CAM, Fiest KM, Frolkis AD *et al*. (2016) Global birth prevalence of spina bifida by folic acid fortification status: a systematic review and meta-analysis. *Am J Public Health* **106**, e24–e34.

109. Kancherla V, Wagh K, Johnson Q *et al*. (2018) A 2017 global update on folic acid-preventable spina bifida and anencephaly. *Birth Defects Res*, 1–9.

110. Parker SE, Mai CT, Canfield MA *et al*. (2010) Updated national birth prevalence estimates for selected birth defects in the United States, 2004-2006. *Birth Defects Res (Part A)* **88**, 1008–1016.

111. Williams J, Mai CT, Mulinare J *et al*. (2015) Updated estimates of neural tube defects prevented by mandatory folic acid fortification-United States, 1995-2011. *MMWR Morb Mortal Wkly Rep* **64**, 1–5.

112. Crider KS, Qi YP, Devine O *et al*. (2018) Modeling the impact of folic acid fortification and supplementation on red blood cell folate concentrations and predicted neural tube defect risk in the United States: have we reached optimal prevention? *Am J Clin Nutr* **107**, 1027–1034.

113. De Wals P, Tairou F, Van Allen MI *et al*. (2007) Reduction in neural-tube defects after folic acid fortification in Canada. *N Engl J Med* **357**, 135–142.

114. Khoshnood B, Loane M, Walle H De *et al*. (2015) Long term trends in prevalence of neural tube defects in Europe: population based study. *Br Med J* **351**, h5949.

115. Botto LD, Lisi A, Robert-Gnansia E *et al*. (2005) International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? *Br Med J* **330**, 571–573.

116. Obeid R, Pietrzik K, Oakley GP *et al*. (2015) Preventable spina bifida and anencephaly in Europe. *Birth Defects Res (Part A)* **103**, 763–771.

117. Boyle B, Addor M-C, Arriola L *et al*. (2018) Estimating global burden of disease due to congenital anomaly: an analysis of European data. *Arch Dis Child Fetal Neonatal Ed* **103**, F22–F28.

118. SACN (2017) *Update on folic acid*.

119. Kelly P, McPartlin J, Goggins M *et al*. (1997) Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. *Am J Clin Nutr* **65**, 1790–1795.

120. Dickinson CJ (1995) Does folic acid harm people with vitamin B12 deficiency? *QJM* **88**, 357–364.

121. Morris MS, Jacques PF, Rosenberg IH *et al*. (2010) Circulating unmetabolized folic acid and 5-methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. *Am J Clin Nutr* **91**, 1733–1744.

122. Clarke R, Sherliker P, Hin H *et al*. (2008) Folate and vitamin B12 status in relation to cognitive impairment and anaemia in the setting of voluntary fortification in the UK. *Br J Nutr* **100**, 1054–1059.

123. Mills JL, Carter TC, Scott JM *et al*. (2011) Do high blood folate concentrations exacerbate metabolic abnormalities in people with low vitamin B-12 status? *Am J Clin Nutr* **94**, 495–500.

124. Cole BF, Baron JA, Sandler RS *et al*. (2007) Folic acid for the prevention of colorectal adenomas. *JAMA* **297**, 2351–2359.

125. Vollset SE, Clarke R, Lewington S *et al*. (2013) Effects of folic acid on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals. *Lancet* **381**, 1029–1036.

126. Keum N & Giovannucci EL (2014) Folic acid fortification and colorectal cancer risk. *Am J Prev Med* **46**, S65–S72.

127. Sweeney MR, Staines A, Daly L *et al*. (2009) Persistent circulating unmetabolised folic acid in a setting of liberal voluntary folic acid fortification. Implications for further mandatory fortification? *BMC Public Health* **9**, 295.

128. Dunstan JA, West C, McCarthy S *et al*. (2012) The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhood. *Allergy Eur J Allergy Clin Immunol* **67**, 50–57.

129. Obeid R, Kasoha M, Kirsch SH *et al*. (2010) Concentrations of unmetabolized folic acid and primary folate forms in pregnant women at delivery and in umbilical cord blood. *Am J Clin Nutr* **92**, 1416–1422.

130. Plumptre L, Masih SP, Ly A *et al*. (2015) High concentrations of folate and unmetabolized folic acid in a cohort of pregnant Canadian women and umbilical cord blood. *Am J Clin Nutr* **102**, 848–857.

131. Houghton LA, Sherwood KL, Pawlosky R *et al*. (2006) [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. *Am J Clin Nutr* **83**, 842–850.

132. Sweeney MR, McPartlin J, Weir DG *et al*. (2005) Evidence of unmetabolised folic acid in cord blood of newborn and serum of 4-day-old infants. *Br J Nutr* **94**, 727–730.

133. Pentieva K, Selhub J, Paul L *et al*. (2016) Evidence from a randomized trial that exposure to supplemental folic acid at recommended levels during pregnancy does not lead to increased unmetabolized folic acid concentrations in maternal or cord blood. *J Nutr* **146**, 494–500.

**Table 1.** Summary of observational studies investigating the association between maternal folate status and cognitive performance of the offspring

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Country** | ***n*** | **Maternal folate status, timing** | **Age of child** | **Cognitive assessment** | **Main findings** |
| *Studies in early pregnancy* | | | | | | |
| Julvez *et al.*(42) | Spain | 420 | Self-reported,  1st trimester | 4 years | MSCA | FA supplement usage associated with improved cognitive performance and decreased inattention. |
| del Rio Garcia *et al.*(43) | Mexico | 253 | Self-reported,  1st trimester | 1, 3, 6 & 12 months | BSID | Lower maternal dietary folate reduced psychomotor and mental development only among children of mothers who had the *MTHFR* 677TT genotype. |
| Schlotz *et al.*(44) | UK | 100 | Blood sample  at 14th GW | 8 years | SDQ | Lower folate status associated with hyperactivity & peer problems in childhood. |
| Roth *et al.*(45) | Norway | 38,954 | Self-reported,  1st trimester | 3 years | LGS | Maternal FA supplement usage associated with reduced risk of severe language delay. |
| Villamor *et al.*(46) | USA | 1,210 | Self-reported,  1st & 2nd trimester | 3 years | PPVT & WRAVMA | FA supplementation in early pregnancy associated with increased cognitive performance. |
| Boeke *et al.*(47) | USA | 813 | Self-reported,  1st & 2nd trimester | 7 years | WRAML & KBIT | No association between maternal folate or vitamin B12 and visual memory. Higher maternal choline intake associated with better child memory score. |
| Polanska *et al.*(48) | Poland | 500  340 | Self-reported,  1st trimester | 1 year  2 years | BSID | FA supplement usage associated with increased cognitive performance, although not significant. |
| Murphy *et al.*(49) | Spain | 67  76 | Blood sample at preconception, 8th GW, cord & child | 4 months  6 years | BSID  WPPSI | Elevated preconception tHcy is associated with reduced psychomotor & cognitive development. |
| *Studies in later pregnancy* | | | | | | |
| Gross *et al.*(50) | Africa | 14 | Diagnosed megaloblastic anaemia, 3rd trimester | 6 weeks –  4 years | DDST | Severe sub-optimal maternal folate status associated with abnormal neurodevelopment and lower intellectual abilities. |
| Tamura *et al.*(51) | USA | 355 | Blood sample at 19th, 26th & 37th GW | 5.3 years | DAS | No association between maternal folate status and cognitive performance. |
| Veena *et al.*(52) | India | 536 | Blood sample  at 30th GW | 9-10 years | K-ABCKM | Higher maternal folate status associated with better cognitive performance. |
| Chatzi *et al.*(53) | Greece | 553 | Self-reported, 14-18th GW & cord blood | 18 months | BSID | FA supplement usage (5 mg/d) associated with enhanced expressive, vocabulary & verbal skills. |
| Wu *et al.*(54) | Canada | 154 | Blood sample  at 16th & 36th GW | 18 months | BSID | No association with maternal folate at 16th or 36th GW and infant neurodevelopment. |
| Valera-Gran *et al*.(55) | Spain | 2,213 | Self-reported,  2nd & 3rd trimester | 14 months | BSID | Dietary FA (0.4 mg/d) during pregnancy related to better mental development than high FA (>5 mg/d) associated with lower psychomotor scores. |
| Ars *et al.*(56) | Netherlands | 256 | Blood sample  at 13.5 GW | 6-8 years | NEPSY & MRI | Low folate status at 13.5 GW associated with reduced brain volume (MRI), lower language and visuospatial subtests results. |
| Valera-Gran *et al.*(57) | Spain | 1,682 | Self-reported,  2nd & 3rd trimester | 4-5 years | MSCA | FA (>1 mg/d) in periconception period associated with reduced verbal and cognitive development. |

MSCA, McCarthy Scales of Children’s Abilities; FA, folic acid; BSID, Bayley Scales of Infant and Toddler Development; SDQ, Strengths and Difficulties Questionnaire; LGS, language grammar scale; PPVT, Peabody Picture Vocabulary Test; WRAVMA, Wide Range Assessment of Visual Motor Abilities; WRAML, Wide Range Assessment of Memory and Learning; KBIT, Kaufman Brief Intelligence Test; WPPSI, Weschler Preschool and Primary Scale of Intelligence; tHcy, total plasma homocysteine; DDST, Denver Developmental Screening Test; DAS, Differental Ability Scales; K-ABCKM, Kaufman Assessment Battery for Children; GW, gestational week, NEPSY, A Developmental NEuroPSYchological Assessment; MRI, magnetic resonance imaging.

**Table 2.** Summary of randomised trials investigating the effect of maternal folic acid supplementation and cognitive performance of the offspring

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Country** | ***n*** | **Maternal Intervention, timing** | **Age of child** | **Cognitive assessment** | **Main findings** |
| Dobo & Czeizel(66) | Hungary | 336  289 | Multivitamin containing FA (0.8 mg/d) vs placebo, Preconception until 8th GW | 2 years  6 years | Brunet-Lezine & Binet tests | No association between periconceptional multivitamin supplementation and cognitive development. |
| Christian *et al.*(67) | Nepal | 676 | FA, Iron/FA, iron/FA/zinc or MMN,  11th GW to 3 months postpartum | 7-9 years | UNIT & MABC | Iron/FA maternal supplementation associated with better intellectual, executive & motor function. |
| Campoy *et al.*(68) | Europe | 154 | Fish oil and/or 5-MTHF vs placebo, 20th GW until birth | 6.5 years | K-ABCKM | No association between fish oil and/or 5-MTHF supplementation on cognitive performance. |
| Pentieva *et al.*(72) | Northern Ireland | 39 | FA vs placebo, 2nd & 3rd trimesters | 3 years | BSID | Maternal FA supplementation associated with increased cognitive performance. |
| Prado *et al.*(69) | Indonesia | 487 | Iron/FA or MMN,  Throughout pregnancy until 3 months postpartum | 3.5 years | Motor, language, non-verbal cognitive & socio-emotional development | MMN supplementation associated with improved motor & cognitive abilities compared to iron/FA alone (specifically visual attention/spatial ability). |
| McGarel *et al.*(73) | Northern Ireland | 72 | FA vs placebo, 2nd & 3rd trimesters | 7 years | WPPSI | Maternal FA supplementation associated with increased word processing. |
| Catena *et al.*(70) | Europe | 136 | Fish oil and/or 5-MTHF vs placebo, 20th GW until birth | 8.5 years | Attention Network Test & EEG | Maternal 5-MTHF supplementation associated with improved conflict solving ability (executive function). |
| Prado *et al.*(71) | Indonesia | 2,879 | Iron/FA or MMN,  Throughout pregnancy until 3 months postpartum | 9-10 years | Motor, language, non-verbal cognitive & socio-emotional development | MMN supplementation long-term benefits for child cognitive development compared to iron/FA alone (specifically procedural memory and general intellectual ability). |

FA, folic acid; GW, gestational week; UNIT, Universal Nonverbal Intelligence Test; MABC, Movement Assessment Battery for Children; 5-MTHF, 5-methyltetrahydrofolate; K-ABCKM, Kaufman Assessment Battery for Children; BSID, Bayley Scales of Infant and Toddler Development; MMN, multiple micronutrient; WPPSI, Weschler Preschool and Primary Scale of Intelligence; EEG, electroencephalography.

FA dosage is 0.4mg/d, unless otherwise stated.

FIGURE LEGEND

**Figure 1**. (Colour online) Overview of one-carbon metabolism. BHMT, betaine homocysteine methyltransferase; CBS, cystathionine-beta-synthase; CTH, cystathionine gamma-lyase; DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dTTP, deoxythymidine triphosphate; FAD, flavin adenine dinucleotide; GNMT, glycine N-methyltransferase; MAT, methionine adenosyltransferase; MS, methionine synthase; MT, methyl transferases; MTHFR, methylenetetrahydrofolate reductase; MTHFD, methylenetetrahydrofolate dehydrogenase; SAHH, S-adenosyl homocysteine hydrolase; SHMT, serine hydroxymethyltransferase; TS, thymidylate synthase. (Adapted from James *et al*. (2017) Epigenetics, nutrition and infant health. In *The Biology of the First 1000 Days*, [KD Karakochuk, KC Whitfield, TJ Green, K Kraemer, editors]. Florida: CRC Press).